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PGS2
ASSESSMENT OF THE UTILITY OF SALSALATE
WITHIN A COX-2 INHIBITOR CLINICAL USAGE
PROTOCOL
Boggie DT, Schaefer MG, DeLattre ML, Morreale AP,
Plowman BK
Veterans Affairs San Diego Healthcare System (119), San
Diego, CA, USA
OBJECTIVES: Prior to approval of COX-2 inhibitor
therapy, a trial of salsalate alone or combined with 
acetaminophen is recommended by local COX-2
inhibitor guidelines. Our objective is to assess the persis-
tence of therapy, safety, and healthcare resource utiliza-
tion of salsalate therapy in the context of COX-2 usage
guidelines. METHODS: Disapproved COX-2 requests
from September 2000 to September 2002 that were sub-
sequently prescribed salsalate were included for analysis.
The evaluation period extended six months from salsalate
initiation in each patient. After excluding patients
without baseline GI Risk Scores, 41 patients remained for
analysis. The primary efﬁcacy outcome was persistence of
salsalate therapy through the evaluation period. Those
who stopped therapy were categorized as having adverse
events or lack of efﬁcacy. The primary safety outcome
was number of adverse drug events. Baseline characteris-
tics of patients who discontinued salsalate and those who
persisted were compared by unpaired t-test. Healthcare
resource utilization for patients included in the analysis
will be presented. RESULTS: Patients had a mean age of
63 ± 13.5 years, mean GI risk score 18 ± 4.8, and mean
daily salsalate dose of 2.0 ± 0.8 grams. There were 
no statistically signiﬁcant differences in characteristics
between patients who discontinued salsalate therapy and
those that persisted. The majority of patients were treated
for osteoarthritis (51%) or chronic pain (44%). Eighteen
patients persisted with salsalate therapy at 6 months
(43.9%). Treatment was discontinued in 23 patients
(56.1%) with 5 patients experiencing adverse events
(12.2%). Adverse events reported were gastrointestinal
upset (7.3%), diarrhea (4.8%), and tinnitus (2.4%). Eigh-
teen patients discontinued salsalate due to lack of efﬁcacy
(43.9%). CONCLUSIONS: Within a COX-2 usage
guideline, approximately half of patients persisted on sal-
salate with few observed adverse events. The high dis-
continuation and low side effect rates may be attributable
to a lower mean daily dose of salsalate in our population.
PGS3
LOW DOSE ESOMEPRAZOLE (20MG) USE IN
GENERAL PRACTICE:A RETROSPECTIVE AUDIT
Hayes AK1, Hinkley K2, Emmas CE2
1Brighstone Surgery, Brighstone, Isle of Wight, United
Kingdom; 2AstraZeneca UK Ltd, Luton, Bedfordshire, United
Kingdom
OBJECTIVES: Esomeprazole is the ﬁrst proton pump
inhibitor (PPI) to show higher healing rates and faster 
sustained relief when compared to omeprazole and 
lansoprazole. Esomeprazole 20mg has been shown to be
effective in the long-term treatment of patients with gas-
troesophageal reﬂux disease (GORD). However there are
no published studies that assess the use of esomeprazole
in routine clinical practice in a UK primary care setting.
METHODS: A retrospective audit of practice records was
performed in a general practice that had made esomepra-
zole its PPI of choice in early 2001 to determine the clin-
ical and cost implications of the change. RESULTS: The
audit identiﬁed 180 patients previously on regular PPI
therapy who had commenced treatment with esomepra-
zole. One hundred ﬁfty patients were prescribed low dose
esomeprazole (20mg) at the time of their initial therapy
change and 146 of these patients were previously on a
standard/high dose PPI. After 6 months 137/146 (94%)
of these patients remained on esomeprazole 20mg. The
majority of patients had no speciﬁc diagnosis but had
been treated symptomatically. Reassuringly of those
patients who did have a speciﬁcally recorded diagnosis of
reﬂux oesophagitis or GORD 41/43 (95%) remained on
esomeprazole 20mg after 6 months. Prior to the change
in therapy to esomeprazole, only 4/180 (2%) of patients
were treated with a low dose PPI. Six months after their
ﬁrst prescription for esomeprazole, 142/180 (79%)
patients remained on esomeprazole 20mg and a further
5 patients were no longer being treated with any PPI. In
addition, savings in PPI costs achieved during the ﬁrst 6
months after the 146 patients’ changed from standard/
high dose PPI therapy to esomeprazole 20mg was £7222.
CONCLUSION: Changing the therapy of patients on
regular standard/high dose PPI to esomeprazole 20mg is
a successful strategy; with very few patients switching
back to a higher dose.
PGS4
EFFECT OF COMPETITION ON ANTIULCER-
GASTRIC-MEDICATION ACQUISITION COSTS
FOR THE MEDICAID PROGRAM
Guo JJ, Pasquale MK, Cluxton RJ, Moomaw CJ,
Zimmerman J, Patel A, Heaton PC, Kelton CML
University of Cincinnati, Cincinnati, OH, USA
OBJECTIVES: To determine the effect of generic drug
competition and new brand product entry on drug acqui-
sition costs for Medicaid. METHODS: Using the Ohio
Medicaid pharmacy claims database, we construct quar-
terly per-prescription reimbursement ﬁgures for each of
the individual brand-name and generic antiulcer gastric
medications (i.e., proton pump inhibitors (PPIs), H2
antagonists, and Carafate) from quarter 1, 1997, through
quarter 3, 2002. The drug acquisition cost for each
generic and brand-name drug is calculated as the per-
prescription reimbursement less an estimate of the Med-
icaid rebate per prescription using the rules as explained
in a recent Kaiser Commission report. A pooled cross-
section, time-series regression model is estimated using
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ordinary least squares. Percentage change in per-
prescription acquisition cost is regressed on change in the
producer price index for ﬁnished goods, change in the
number of generic and brand-name antiulcer drugs,
change in the number of brand name drugs in the sub-
market (PPIs or H2 antagonist or Carafate), and per-
centage change in the number of generic manufacturers.
RESULTS: The acquisition cost for generic prescriptions
decreases over time. With the exception of Pepcid, the
acquisition costs for H2 drugs rise fairly steadily through-
out the study period. All of the PPIs have rising per-
prescription acquisition costs. For generic drugs, the rise
of number of generic companies has a signiﬁcant negative
impact on generic drug acquisition costs (p = 0.0004).
Neither the change in the producer price index nor any
change in the number of drugs in the drug’s smaller or
wider market has a signiﬁcant impact on acquisition-cost
change (p > 0.10). CONCLUSIONS: The cost beneﬁt to
Medicaid from a rise in competition is being passed on in
terms of lower acquisition costs for generic drugs.
Branded medications continue to show a rise in cost per
script.
PGS5
ECONOMIC ASSESSMENT OF DRUGS AND GI
HOSPITALIZATIONS ASSOCIATED WITH
APPLYING VA CRITERIA FOR PRESCRIBING
NONSTEROIDAL ANTI-INFLAMMATORY
AGENTS
Harris CL1, Raisch DW2
1VA Cooperative Studies Program, Albuquerque, NM, USA;
2VA Cooperative Studies Program Clinical Research
Pharmacy Coordinating Center, Albuquerque, NM, USA
OBJECTIVE: The purpose of this study was to assess the
cost impact of applying VA Criteria for use of non-
steroidal anti-inﬂammatory drugs (NSAID). METHODS:
These criteria utilize a self-administered Gastrointestinal
(GI) Risk Assessment Tool (GI Score). The GI Score is a
composite scale used to predict the 1-year risk level for
an NSAID-associated GI event (no risk to substantial
risk). The risk levels for patients at three facilities were
calculated from VA databases regarding demographic,
prescription, hospitalizations, and active problem lists.
Cost analysis was limited to 2002 VA drug costs and esti-
mated GI-event hospitalization. The perspective was the
VA Healthcare System. We assumed no difference in hos-
pitalized GI event rates between NSAID with a PPI or
COX-2 inhibitor. RESULTS: There were 19,123 NSAID
users at three VA Medical Centers. The following GI
Score risk factors were found in these patients: 212 GI
hospitalization, 212 concurrent warfarin therapy, 725
corticosteroid therapy, and 583 rheumatoid arthritis.
There were 36% over the age of 65. Thirty-two percent
of the patients (n = 6126) were at high risk for a GI event;
8% substantial and 24% signiﬁcant. The actual annual
drug costs for high risk and low risk patients were
$471,898 ($77.02/patient) and $291,960 ($22.46/
patient), respectively. Switching to criteria-based therapy
is estimated to save 14.7 hospitalizations among the high
risk patients. For high risk patients, the base case of
adding a PPI to current therapy with decreased GI-
associated hospitalizations resulted in a cost of $278,809
($45.51/patient/year). We applied alternative therapies
for sensitivity analysis, switching all high risk patients 
to a low-cost NSAID with a PPI ($73,433 or $11.99/
patient/year) or a COX-2 inhibitor ($1,389,686 or
$226.85/patient/year). CONCLUSIONS: Our results
suggest the criteria-based therapy (base case) could result




THE COST-EFFECTIVENESS OF ALTERNATIVE
STRATEGIES IN THE MANAGEMENT OF
PATIENTS WITH UNINVESTIGATED DYSPEPSIA
(UD): COMPARING THE CANDYS APPROACH TO
EMPIRICAL ANTISECRETORY THERAPY AND
PROMPT ENDOSCOPY
Barkun A1, Crott R2, Fallone CA1, Kennedy WA3, Lachaine J3,
Levinton C3,Armstrong D4, Chiba N5,Thomson ABR6,
Veldhuyzen Van Zanten SJO7, Sinclair P8, Chakraborty B9,
Escobedo S9, Smyth S9,White RE9, Nevin K9
1McGill University Health Centre, Montreal, QC, Canada;
2University of Montreal and EORTC, Brussels, Belgium;
3University of Montreal, Montreal, QC, Canada; 4McMaster
University, Hamilton, ON, Canada; 5McMaster University,
Guelph, ON, Canada; 6University of Alberta, Edmonton, AB,
Canada; 7Dalhousie University, Halifax, NS, Canada; 8CAG
National Ofﬁce, Oakville, ON, Canada; 9AstraZeneca Canada
Inc, Mississauga, ON, Canada
OBJECTIVES: Examine optimal cost-effective manage-
ment of adult patients with uninvestigated dyspepsia
(UD). METHODS: We compared the CanDys approach
(acid suppression for patients with heartburn predomi-
nant symptoms, and a test-and-treat strategy for others,
treating H. pylori negative (HP-) patients with acid sup-
pression and HP+ patients with eradication) to empirical
antisecretory therapy (EAS) and prompt endoscopy (PE).
All patients presented with UD. EAS was 4 weeks of
omeprazole 20mg od or ranitidine 150mg bid. The unit
of effectiveness was the proportion of patients symptom-
free (SF) at four weeks. Probability assumptions were
obtained from literature or expert opinion. Direct costs
(in 1999 CAN$) for diagnostic tests, physician visits, and
medications were derived from provincially set fees. The
analysis was conducted using a Monte Carlo simulation
in Data 4.0 that incorporated distributions for all vari-
ables with elasticities greater than 0.3 (for efﬁcacy or
cost). Sensitivity analyses were carried out across clini-
cally relevant ranges of important probability and cost
variables. RESULTS: Of the non-dominated strategies,
